ARTICLE
11 March 2022

Timing Is Everything — Intervening Loss In Standing Results In Dismissal Of Appeal

WT
Winston Taylor

Contributor

Whether you're leading the way, disrupting an industry, entering a new phase of growth, or launching a defining product—we're in the room with you. In the action. Sleeves rolled up.

With a rich history spanning both sides of the Atlantic, we are present in the major commercial centers that matter to our clients: the U.S., the U.K., Europe, Latin America, and the Middle East. Combining scale with the speed clients demand, our defining capabilities include major litigation, critical transactions, strategic IP, and private wealth.

Our team of over 1,400 lawyers works hand-in-hand across markets, sectors, practice areas, and client teams. All-in problem solvers, we bring the creativity to think differently, and the pragmatism to get things done when it counts the most.

Embedded in your business and sharing your ambition, we take the work personally. Shaping what we do and how we do it around your goals and needs, always one step ahead of the moment.

ModernaTx, Inc. v. Arbutus Biopharma Corporation, No. 2020-1184, 2020-1186 (Fed. Cir. Dec. 1, 2021)...
United States Intellectual Property

ModernaTx, Inc. v. Arbutus Biopharma Corporation, No. 2020-1184, 2020-1186 (Fed. Cir. Dec. 1, 2021)

Petitioner appealed an adverse decision from the PTAB holding certain claims of a patent were not unpatentable. The Federal Circuit dismissed the appeal for lack of standing.

While there is no standing requirement to file a request to institute an IPR, a petitioner must show Article III standing to appeal any resulting decision. The petitioner argued it had standing at the time it filed the appeal as a licensee of the patent having monetary obligations impacted by the PTAB's decision. The Federal Circuit disagreed. First, it found that the last payment petitioner made under the license was more than five years prior to the filing of the appeal, which fell short of demonstrating it was suffering a concrete injury at the time of the appeal. Second, the court found that the license included many patents, and the petitioner had not shown that invalidation of this particular patent would change its royalty obligations (if any).

The Federal Circuit also found petitioner had not shown continuous standing throughout pendency of the appeal. Nine months after it filed its opening brief in the appeal, petitioner filed a motion to supplement the record and shifted its basis for standing during the appeal, arguing that while its development program (that was subject to the above-described license) had ended at some point, it still had standing due to a risk of an infringement suit for its COVID-19 vaccine. Petitioner pointed to the patent owner's public statements on the scope of the patents, refusal to grant a covenant not to sue, and insistence that a license was required as evidence of a significant risk that it would be sued for infringement. But the Federal Circuit concluded it was “impossible to determine” whether by the time the licensed program had terminated, petitioner was sufficiently underway with its development of its COVID-19 vaccine. Petitioner had not even provided an approximate date of termination. As such, the Federal Circuit found the evidence showed a gap in petitioner's standing evidence and dismissed the petitioner's appeal.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More